By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

Moderna agreed to pay up to $2.25 billion to settle a long‑running COVID vaccine patent dispute. The deal ends years of legal challenges.

Is Pfizer stock the only big pharma name I'd buy and hold through any market crash? Let's find out. Image source: Getty ...

As the midterm elections approach, the health secretary is focusing on “real food.” Anger is rising among some of his supporters.

Those were in great demand at the beginning of the pandemic, and generated gobs of money for Pfizer. Demand has waned, though ...

Pfizer (NYSE:PFE) is stepping deeper into the global weight loss race, striking a deal with Hangzhou Sciwind Bioscience for exclusive commercialization rights to ecnoglutide in mainland China, in an ...

Booster vaccines reduced the risk of COVID‑19–related hospitalization and death, according to a new study of over 3 million ...

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the ...

Moderna, Inc. settles LNP patent dispute for $950M, securing royalty-free tech access and legal clarity; click for what it ...

Maternal respiratory syncytial virus vaccination appeared to be safe and effective for mothers with HIV and their infants, according to data presented at the Conference on Retroviruses and ...

Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...

We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE’s share was trading at $103.80 as of March 4th.